A

Alexion

Global biopharmaceuticals focusing on rare diseases

Key Customer Lead - IgA nephropathy

Marketing Generalist & ManagementConfirmed live in the last 24 hours
Full-timeTokyo, JapanNo salary listedIn-person

About the Job

Requirements

  • Requires specialized knowledge of the renal disease area.
  • Requires strategic thinking.
  • Requires strong interpersonal and communication skills.
  • Requires objective analytical ability.
  • Requires strong reading comprehension of English-language papers.
  • Requires skills creating materials in Excel and PowerPoint.
  • Requires project management experience, such as for CSP seminars.

Responsibilities

  • Build relationships with key opinion leaders (KOLs) in hematology and renal disease areas, train them as speakers, and support their development while leading marketing and sales strategy execution through the Commercial Speaker Program (CSP) and other marketing initiatives.
  • For the IgA nephropathy area, where an indication expansion is planned, build relationships with KOLs, train speakers, support their development, and lead the area through CSP and marketing initiatives in collaboration with relevant departments.
  • Clarify KOL profiles and influence maps, create engagement plans for KOL development, manage progress, and propose CSP activities.
  • Propose the structure and core slides for speaker slide decks, support slide review, and guide speakers.
  • Monitor new insights and treatment changes in related disease areas that may affect marketing strategy, collaborate with Medical Affairs, and provide feedback to Marketing.
  • Train speakers and chairpersons and guide them to comply with Alexion's requirements when giving presentations.
  • Collaborate with field partners, such as Medical Science Liaisons, to develop KOLs for shared customers in a complementary manner.

Desired Qualifications

  • Experience supporting the hematology or renal disease areas.
  • Marketing or sales experience in rare diseases.
  • Marketing or sales experience around the launch of a new product.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs